Scientia Advisors in the News
Drug Wars - How GSK is trying to reinvent itself as a pharmaceutical giant by using the acquisition model rather than relying on its R&D pipelineFrank Vinluan
May 14, 2010
This article discusses why past strategy of replacing revenue from patent-challenged drugs with other blockbuster products will no longer work for big pharmaceutical companies. The author quotes Harry Glorikian, managing partner at Scientia Advisors who explains the new strategy model involving personalized medicine and the upcoming challenges for big pharma firms.
Read article at: Triangle Business Journal